Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.70 |
| ▸ | GAA | P10253 | 2/20 | 0.70 |
| ▸ | HSPB1 | P04792 | 2/20 | 0.68 |
| ▸ | MAPT | P10636 | 8/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | HTT | P42858 | 3/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3133376 | 0.91 | GAA (0.62) | L3MBTL1GAAHSPB1MAPTNPSR1 | |
| SCHEMBL3143134 | 0.87 | GAA (0.64) | L3MBTL1GAAHSPB1MAPTNPSR1 | |
| SCHEMBL20932230 | 0.86 | HSPB1 (0.82) | L3MBTL1GAAHSPB1MAPTNPSR1 | |
| SCHEMBL3139649 | 0.86 | GAA (0.70) | L3MBTL1GAAHSPB1MAPTNPSR1 | |
| SCHEMBL3143148 | 0.86 | L3MBTL1 (0.70) | L3MBTL1GAAHSPB1MAPTNPSR1 | |
| SCHEMBL7807343 | 0.84 | L3MBTL1 (0.68) | L3MBTL1GAAHSPB1MAPTNPSR1 | |
| SCHEMBL29351869 | 0.84 | HSPB1 (0.55) | L3MBTL1GAAHSPB1MAPTNPSR1 | |
| SCHEMBL22530112 | 0.84 | HSPB1 (0.55) | L3MBTL1GAAHSPB1MAPTNPSR1 | |
| SCHEMBL10466511 | 0.84 | HSPB1 (0.73) | L3MBTL1GAAHSPB1MAPTNPSR1 | |
| SCHEMBL3967877 | 0.83 | GAA (0.67) | L3MBTL1GAAHSPB1MAPTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1790637-B1 | Derivatives of N-4-piperidyl urea and medicaments containing them as active ingredient | ONO PHARMACEUTICAL CO (JP) | 2014-01-29 | — | — | EP | disclosed |
| US-8604207-B2 | Nitrogenous heterocyclic derivative and medicine containing the same as an active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-12-10 | — | — | US | disclosed |
| US-20130085275-A1 | NITROGENOUS HETEROCYCLIC DERIVATIVE AND MEDICINE CONTAINING THE SAME AS AN ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-04-04 | — | — | US | disclosed |
| US-8410276-B2 | Nitrogenous heterocyclic derivative and medicine containing the same as an active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-04-02 | — | — | US | disclosed |
| EP-2546234-A1 | Nitrogeneous heterocyclic derivative and medicine containing the same as an active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-8143404-B2 | N-heterocycle urea compounds such as 5-([(butyl{1-[(2-methyl-6-{4-[(methylsulfonyl)amino]phenoxy)-3-pyridinyl)methyl]-4-piperidinyl}amino)carbonyl]amino)-2,4-difluorobenzamide; chemokine receptor CCR5 antagonists for various inflammatory diseases, autoimmune diseases, infectious diseases | ONO PHARMACEUTICAL CO., LTD (JP) | 2012-03-27 | — | — | US | disclosed |
| US-20110152520-A1 | NITROGENOUS HETEROCYCLIC DERIVATIVE AND MEDICINE CONTAINING THE SAME AS AN ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-06-23 | — | — | US | disclosed |
| US-20080057074-A1 | Nitrogenous Heterocylic Derivative and Medicine Containing the Same as an Active Ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-03-06 | — | — | US | disclosed |
| EP-1790637-A1 | NITROGENOUS HETEROCYCLIC DERIVATIVE AND MEDICINE CONTAINING THE SAME AS AN ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080057074-A1 | Nitrogenous Heterocylic Derivative and Medicine Containing the Same as an Active Ingredient | CXCR3, CCR5, CCR1 | L3MBTL1 2776/4885GAA 4444/4885HSPB1 660/4885 |
| US-20110152520-A1 | NITROGENOUS HETEROCYCLIC DERIVATIVE AND MEDICINE CONTAINING THE SAME AS AN ACTIVE INGREDIENT | CXCR3, CCR5, CCR1 | L3MBTL1 2951/4885GAA 4350/4885HSPB1 906/4885 |
| US-20130085275-A1 | NITROGENOUS HETEROCYCLIC DERIVATIVE AND MEDICINE CONTAINING THE SAME AS AN ACTIVE INGREDIENT | CXCR3, CCR5, CCR1 | L3MBTL1 2951/4885GAA 4350/4885HSPB1 906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.